LUMIZYME
Drug
GENZYME CORPORATION
Total Payments
$9.1M
Transactions
3,715
Doctors
1,257
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.6M | 269 | 73 |
| 2023 | $2.0M | 398 | 55 |
| 2022 | $655,208 | 86 | 31 |
| 2021 | $891,236 | 228 | 135 |
| 2020 | $622,975 | 344 | 116 |
| 2019 | $1.6M | 912 | 379 |
| 2018 | $1.1M | 934 | 516 |
| 2017 | $623,956 | 544 | 280 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.4M | 835 | 81.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $698,078 | 326 | 7.7% |
| Consulting Fee | $597,415 | 134 | 6.6% |
| Travel and Lodging | $244,920 | 496 | 2.7% |
| Food and Beverage | $73,945 | 1,904 | 0.8% |
| Space rental or facility fees (teaching hospital only) | $35,850 | 19 | 0.4% |
| Education | $3.50 | 1 | 0.0% |
Payments by Type
Research
$7.4M
835 transactions
General
$1.7M
2,880 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ESC-Project 2 -Long-term Follow-up and Treatment Outcomes for Individuals with Pompe Disease: Role of the Immune System | GENZYME CORPORATION | $927,802 | 0 |
| Duke Center of Excellence Program | GENZYME CORPORATION | $926,746 | 0 |
| Investigating Pompe Prevalence in NEuromuscular Medicine Academic Practices (IPANEMA Study) | GENZYME CORPORATION | $844,834 | 0 |
| ESC-Project 1 -Insights and characterization into the central and peripheral nervous system involvement in children with Pompe disease | GENZYME CORPORATION | $787,407 | 0 |
| Pompe Disease Registry | SANOFI US SERVICES INC. | $633,360 | 0 |
| Evaluation of children with the late-onset Pompe disease GAA variants identified by newborn screening: Guidance for in person or virtual monitoring | GENZYME CORPORATION | $613,380 | 0 |
| Defining Central Nervous System Abnormalities in Infantile and Late-Onset Pompe Disease Patients | GENZYME CORPORATION | $370,989 | 0 |
| Immunophenotyping of infantile Pompe disease | GENZYME CORPORATION | $361,268 | 0 |
| Developmental outcomes of school-aged children with infantile-onset Pompe disease: A telemedicine approach to assessment and cognitive training. | GENZYME CORPORATION | $239,052 | 0 |
| A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease | SANOFI US SERVICES INC. | $214,417 | 0 |
| Enabling CNS delivery of rhGAA in GAA-/- mice using focused ultrasound | GENZYME CORPORATION | $203,861 | 0 |
| Electrical Impedance Myography and Muscle Ultrasound: Longitudinal Measures in Pompe Disease | GENZYME CORPORATION | $198,970 | 0 |
| Muscle Imaging at 7 Tesla | GENZYME CORPORATION | $198,714 | 0 |
| A Prospective Observational Study to Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients =6 Months of Age With Infantile-onset Pompe Disease (IOPD) | GENZYME CORPORATION | $102,335 | 0 |
| A Study to Identify Individuals At Risk To Be Affected By Pompe Disease Who Had PrevioUsly Been Given a Non-Specific OR Tentative Diagnosis For Their MUscle Weakness (Pompe PURSUE) | GENZYME CORPORATION | $90,117 | 0 |
| A Phase 3/4 Prospective Study to Characterize the Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease | GENZYME CORPORATION | $76,147 | 0 |
| Safety and Effectiveness of Resistance exercise training in late onset Pompe disease patients- a pilot study | GENZYME CORPORATION | $74,269 | 0 |
| Functional Resolution of Multi-loci Pathogenic Variants and VUSs in Pompe Disease | GENZYME CORPORATION | $72,000 | 0 |
| NCOMP09701 A retrospective, observational study of disease management and clinical comes associated with alglucosidase alfa treatment among patients with infantile-onset Pompet disease | SANOFI US SERVICES INC. | $64,757 | 0 |
| Proteolytic Quantification of GAA in Dried Blood Spots by Peptide Immuno-SRM as a Potential Screen for Immunogenicity in Pompe Disease | GENZYME CORPORATION | $51,090 | 0 |
Top Doctors Receiving Payments for LUMIZYME
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Sacramento, CA | $7.4M | 546 |
| Priya Kishnani | Pediatrics | Durham, NC | $184,790 | 147 |
| , M.D | Physical Medicine & Rehabilitation | Sacramento, CA | $161,198 | 183 |
| , MD | Critical Care Medicine | Boston, MA | $125,205 | 107 |
| , MD | Neurology | Orange, CA | $100,652 | 88 |
| , M.D | Neurology | Phoenix, AZ | $93,268 | 94 |
| , M.D | Internal Medicine | Detroit, MI | $63,924 | 99 |
| , M.D | Pulmonary Disease | New York, NY | $56,504 | 47 |
| , MD | Pediatric Cardiology | Gainesville, FL | $52,963 | 60 |
| , MD | Pediatrics | Valhalla, NY | $39,884 | 50 |
| , M.D | Neurology | Portland, OR | $38,091 | 20 |
| , MD | Clinical Genetics (M.D.) | Greenville, SC | $36,745 | 42 |
| , MD | Pediatrics | Springfield, MA | $25,367 | 34 |
| , MD | Neuromuscular Medicine | Cincinnati, OH | $25,360 | 30 |
| , M.D | Clinical Genetics (M.D.) | Philadelphia, PA | $24,899 | 22 |
| , MD | Clinical Genetics (M.D.) | Orange, CA | $24,581 | 22 |
| , M.D | Neuromuscular Medicine | Kansas City, KS | $24,571 | 45 |
| , M.D | Clinical Genetics (M.D.) | Galveston, TX | $24,340 | 21 |
| , MD | Neurology | Dallas, TX | $23,400 | 15 |
| , M.D., PH.D | Clinical Genetics (M.D.) | Washington, DC | $22,066 | 12 |
| , MD | Neuromuscular Medicine | Los Angeles, CA | $21,088 | 4 |
| , M.D | Clinical Biochemical Genetics | Seattle, WA | $21,041 | 7 |
| , MD | Medical Genetics, Ph.D. Medical Genetics | Valhalla, NY | $20,685 | 26 |
| , M.D | Student in an Organized Health Care Education/Training Program | Fenton, MO | $19,856 | 12 |
| , M.D | Student in an Organized Health Care Education/Training Program | Chicago, IL | $19,275 | 17 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $8.0M
- SANOFI US SERVICES INC. $940,267
- SANOFI-AVENTIS U.S. LLC $110,674
- Genzyme Corporation $68.54
Product Information
- Type Drug
- Total Payments $9.1M
- Total Doctors 1,257
- Transactions 3,715
About LUMIZYME
LUMIZYME is a drug associated with $9.1M in payments to 1,257 healthcare providers, recorded across 3,715 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2024. In 2024, $1.6M was paid across 269 transactions to 73 doctors.
The most common payment nature for LUMIZYME is "Unspecified" ($7.4M, 81.8% of total).
LUMIZYME is associated with 20 research studies, including "ESC-Project 2 -Long-term Follow-up and Treatment Outcomes for Individuals with Pompe Disease: Role of the Immune System" ($927,802).